2000/08-2004/08   
Department of respiration medicine, Affiliated hospital of Guilin Medical College, Resident   and  attending physician

2004/09-2007/06   
Department of MedicalOncology, Cancer center of Sun Yat-sen University,Master of oncology

2007/07-2010/07 
Department of Medical Oncology, Cancer center of Sun Yat-senUniversity, Oncology training Physician

2010/08-Present   
Department of Medical Oncology, Cancer center of Sun Yat-sen University, Attending Physician

Clinical and basic research inmedical oncology and translational medicine,especially in diagnosis and therapy for the gastrointestinal tumor.

1995/09-2000/07    Faculty of Clinical medicine in Guangxi Medical  University, Bachelor of medicine

2004/09-2007/06    Department of Medical Oncology, Cancer center of Sun Yat-sen University, Master ofoncology

2007/07-2010/07    Department of Medical Oncology, Cancer center of  Sun Yat-senUniversity, Oncology training Physician

2012.9-Present       PhD candidate

1.       Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P, Xu RH. Overexpression of the circadian clock gene bmal1increases sensitivity to oxaliplatin in colorectal cancer. Clin Cancer Res. 2014 Feb 15;20(4):1042-52.

2.       Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH.Comparison of the prognostic values of various inflammation based factors inpatients with pancreatic cancer. Med Oncol. 2012Dec;29(5):3092-100.

3.        Luo HY, Wang ZQ, Wang FH, Qiu MZ, Teng KY, RuanDY, He YJ, Li YH, Xu RH. Phase 2 study of capecitabine and irinotecancombination chemotherapy (modified XELIRI regimen) in patients with advancedgastric cancer. Am J Clin Oncol. 2011 Dec;34(6):555-60.

4.       Qiu MZ, Wang ZQ, Luo HY, Zhang DS, Zhou ZW, Li YH, JiangWQ, Xu RH. Prognostic analysis in node-negative gastric cancer patients inChina.Tumour Biol. 2011 Jun;32(3):489-92.

5.       Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, XuRH.Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectalcancer. World J Gastroenterol. 2010 Dec 14;16(46):5881-8.

6.       Qiu MZ, Han B, Luo HY, Zhou ZW, Wang ZQ, Wang FH, LiYH, Xu RH. Expressions of hypoxia-inducible factor-1α and hexokinase-II ingastric adenocarcinoma: the impact on prognosis and correlation toclinicopathologic features.Tumour Biol. 2011 Feb;32(1):159-66.

7.        Luo HY, Wei W, Shi YX, Chen XQ, Li YH, Wang F, QiuMZ, Li FH, Yan SL, Zeng MS, Huang P, Xu RH.Cetuximab enhances the effect ofoxaliplatin on hypoxic gastric cancer cell lines.Oncol Rep. 2010Jun;23(6):1735-45.

8.        Luo HY, Xu RH, Wang F, Qiu MZ, Li YH, Li FH, ZhouZW, Chen XQ.Phase II trial of XELOX as first-line treatment for patients withadvanced gastric cancer. Chemotherapy. 2010;56(2):94-100.

9.       Li YH, Luo HY, Wang FH, Wang ZQ, Qiu MZ, Shi YX, Xiang XJ, Chen XQ, He YJ,Xu RH.Phase II study of capecitabine plus oxaliplatin (XELOX) as first-linetreatment and followed by maintenance of capecitabine in patients withmetastatic colorectal cancer.J Cancer Res Clin Oncol. 2010 Apr;136(4):503-10. 

Updated by International Office, Sun Yat-sen University Cancer Center